Kinetic Imaging Cytometer (KIC) for High Throughput Studies of Cellular Physiology
用于细胞生理学高通量研究的动态成像细胞仪 (KIC)
基本信息
- 批准号:10175806
- 负责人:
- 金额:$ 52.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-26 至 2022-10-25
- 项目状态:已结题
- 来源:
- 关键词:Biomedical EngineeringCardiac MyocytesCardiovascular DiseasesCardiovascular systemCell physiologyCellsComplications of Diabetes MellitusDevelopmentDiseaseDisease modelElectrophysiology (science)EnsureFacultyFaculty RecruitmentFundingGoalsGrantHeart failureImageInstitutesInstitutionKineticsLaboratoriesMaintenanceMedicineMinorOphthalmologyPatient CarePediatricsPhysiologicalPhysiologyPlayProteomeResearchResearch PersonnelResourcesRoboticsRoleScienceSpeedStrategic PlanningSystemTherapeuticTimeUnited States National Institutes of Healthbasecancer therapydrug developmentexperienceheart cellimprovedinduced pluripotent stem cellinnovationinstrumentinstrumentationmedical schoolsoperationpatch clampscreeningsenior facultystem cell modelwhole genome
项目摘要
PROJECT SUMMARY/ABSTRACT:
The Stanford Cardiovascular Institute (CVI) proposes the acquisition of a Vala Sciences’ IC200
Kinetic Imaging Cytometer (KIC) to be placed in a shared setting in the new Biomedical
Innovations (BMI) Building that is centrally located on campus. The IC200 KIC is a cutting edge
instrument that combines aspects of high content screening systems with high speed video
imaging and cell-by-cell analysis features of physiological recording instrumentation such as
patch clamp electrophysiology setups. No other type of instrument combines these features, and
no comparable instrument is available on Stanford campus or in the vicinity. The instrument will
be used for in-depth studies that probe disease mechanisms of excitable cells such as
cardiomyocytes on an unprecedented whole genome and whole proteome level. The focus on
mechanism-based understanding of disease, and ultimately the development of mechanism-
based therapeutics, aligns with the long-term strategic plan of the Stanford CVI and School of
Medicine, and is consistent with recent faculty recruitment. The capability of high throughput
assessment of physiological function of heart cells plays a central role in this plan. The instrument
will be managed by an experienced group with expertise in high content screening and disease
modelling using induced pluripotent stem cell (iPSC)-based models. The CVI comprises more
than 400 investigators and more than 125 faculty-led research groups and spans diverse
departments including Medicine, Pediatrics, Ophthalmology and Biomedical Engineering. The
Major and Minor Users highlighted in this proposal range from junior faculty who are just starting
their own laboratories to established full professors with over 20 years of research experience.
All the major users have NIH funding, and the collective benefit to NIH grants comprises over
80% of the anticipated user time of the instrument. The institution is committing considerable
financial resources and dedicated space to ensure the maintenance and continued operation of
the instrument, including its integration into a robotics facility. We expect that the IC200 will
positively impact a broad cross section of cardiovascular and other diseases, notably heart failure
and cardiovascular complications of diabetes and cancer treatments. In addition, the high
throughput and physiology recording aspects of the IC200 will propel research towards our drug
development and our translational goal of improving care of patients with cardiovascular disease.
项目摘要/摘要:
斯坦福大学心血管研究所(CVI)提议收购Vala Sciences的IC200
动态成像细胞仪(KIC)将被放置在新的生物医学中的共享环境中
位于校园中心的创新(BMI)大楼。IC200 KIC是一款尖端产品
将高内容放映系统与高速视频相结合的仪器
生理记录仪器的成像和逐细胞分析特征,例如
膜片钳电生理学装置。没有其他类型的仪器结合了这些功能,并且
斯坦福校园或附近没有类似的仪器。这台仪器将
用于深入研究可兴奋细胞的疾病机制,如
心肌细胞在前所未有的全基因组和全蛋白质组水平上。重点放在
以机制为基础的对疾病的理解,并最终发展机制--
以治疗学为基础,与斯坦福CVI和
医学,这与最近的教师招聘是一致的。高吞吐量的能力
对心脏细胞生理功能的评估在这一计划中起着核心作用。这台仪器
将由在高含量筛查和疾病方面具有专业知识的经验丰富的团队管理
使用基于诱导多能干细胞(IPSC)的模型进行建模。CVI包括更多
400多名研究人员和125多名教职员工领导的研究小组
包括内科、儿科、眼科和生物医学工程等。这个
本建议书中重点介绍的主要用户和次要用户包括刚开始工作的初级教员
从他们自己的实验室到拥有20多年研究经验的全职教授。
所有主要用户都有NIH资金,NIH赠款的集体收益包括
仪器预期使用时间的80%。该机构正在做出相当大的承诺
财政资源和专用空间,以确保维护和继续运营
该仪器,包括其与机器人设施的集成。我们预计IC200将
积极影响广泛的心血管疾病和其他疾病,特别是心力衰竭
糖尿病和癌症治疗的心血管并发症。此外,高
IC200的吞吐量和生理记录方面将推动我们的药物研究
发展和我们的翻译目标是改善对心血管疾病患者的护理。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK MERCOLA其他文献
MARK MERCOLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK MERCOLA', 18)}}的其他基金
hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
用于药物测试的限制性心肌病的 hiPSC 模型
- 批准号:
10716393 - 财政年份:2023
- 资助金额:
$ 52.83万 - 项目类别:
High throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug development
用于心力衰竭药物开发的心脏生理学同步多参数评估的高通量平台
- 批准号:
10745000 - 财政年份:2023
- 资助金额:
$ 52.83万 - 项目类别:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
将 HCM 中的基因型与表型联系作为治疗策略
- 批准号:
10355529 - 财政年份:2021
- 资助金额:
$ 52.83万 - 项目类别:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
将 HCM 中的基因型与表型联系作为治疗策略
- 批准号:
10576285 - 财政年份:2021
- 资助金额:
$ 52.83万 - 项目类别:
Single-cell Multi-omic Profiling of Drug Responses Using Pooled iPSC-CM Differentiation
使用汇集 iPSC-CM 分化进行药物反应的单细胞多组学分析
- 批准号:
10671175 - 财政年份:2019
- 资助金额:
$ 52.83万 - 项目类别:
相似海外基金
Modeling the spatiotemporal properties of crosstalk between RYR-mediated and IP3R-mediated calcium signaling in cardiac myocytes
模拟心肌细胞中 RYR 介导和 IP3R 介导的钙信号传导之间串扰的时空特性
- 批准号:
10701689 - 财政年份:2022
- 资助金额:
$ 52.83万 - 项目类别:
Understanding the mechanism why cardiac myocytes resist Myc-induced proliferation
了解心肌细胞抵抗 Myc 诱导的增殖的机制
- 批准号:
21K08854 - 财政年份:2021
- 资助金额:
$ 52.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidating molecular mechanisms of magnesium regulation to protect cardiac myocytes against life-style related diseases
阐明镁调节保护心肌细胞免受生活方式相关疾病的分子机制
- 批准号:
20K11518 - 财政年份:2020
- 资助金额:
$ 52.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Host-parasite lipid metabolism in Trypanosoma cruzi-infected cardiac myocytes
克氏锥虫感染心肌细胞中宿主寄生虫的脂质代谢
- 批准号:
10058037 - 财政年份:2020
- 资助金额:
$ 52.83万 - 项目类别:
Host-parasite lipid metabolism in Trypanosoma cruzi-infected cardiac myocytes
克氏锥虫感染心肌细胞中宿主寄生虫的脂质代谢
- 批准号:
10249356 - 财政年份:2020
- 资助金额:
$ 52.83万 - 项目类别:
A System to Optically Determine the Absolute Membrane Potential in Human iPSCD Cardiac Myocytes
光学测定人 iPSCD 心肌细胞绝对膜电位的系统
- 批准号:
10081467 - 财政年份:2020
- 资助金额:
$ 52.83万 - 项目类别:
Intramyocardial magnetic targeting of cardiac myocytes
心肌细胞的心肌内磁靶向
- 批准号:
405831333 - 财政年份:2018
- 资助金额:
$ 52.83万 - 项目类别:
Research Grants
Translational research for the development of novel heart failure therapy that targets signaling pathway in cardiac myocytes
开发针对心肌细胞信号通路的新型心力衰竭疗法的转化研究
- 批准号:
18K08121 - 财政年份:2018
- 资助金额:
$ 52.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)